The Elijah E. Cummings Lower Drug Costs Now Act
WASHINGTON DC (December 13, 2019) – AAM commends the House for its efforts to address the high cost of brand-name drugs and improve the Medicare program for seniors. Generics and biosimilars are vital to reducing spending for patients and taxpayers, and any inflation-based rebates should acknowledge the value of these low-cost medicines by exempting generics and biosimilars. In addition, we encourage Congress to strengthen incentives for generic and biosimilar adoption with the inclusion of the Ensuring Access to Lower-Cost Medicines for Seniors Act (H.R. 4913) from Reps. David McKinley (R-WV) and Ann Kuster (D-NH).
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.